Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $125,059.48 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 72,709 shares of the company’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $1.72, for a total value of $125,059.48. Following the completion of the transaction, the insider directly owned 6,645,961 shares in the company, valued at $11,431,052.92. This trade represents a 1.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Wednesday, October 29th, Ansbert Gadicke sold 134,240 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $208,072.00.
• On Tuesday, October 28th, Ansbert Gadicke sold 69,068 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.64, for a total value of $113,271.52.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $1.31 on Friday. The stock’s fifty day moving average is $1.62 and its two-hundred day moving average is $1.31. The company has a market capitalization of $59.91 million, a PE ratio of -0.80 and a beta of 0.76. The company has a quick ratio of 5.30, a current ratio of 5.30 and a debt-to-equity ratio of 0.60. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $2.75.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.10. As a group, analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds have recently made changes to their positions in HOWL. Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $409,000. Marshall Wace LLP purchased a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $113,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $92,000. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics during the 1st quarter worth $79,000. Finally, Nuveen LLC purchased a new stake in shares of Werewolf Therapeutics during the 1st quarter worth $71,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HOWL. Bank of America lowered their target price on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, August 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. JMP Securities lowered their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Finally, Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.